Skip to main content
dana-farber.org
Dana-Farber
  • person
  • Search
  • Featured Specialties
    • Breast Oncology
    • Gastrointestinal Oncology
    • Genitourinary Oncology
    • Gynecologic Oncology
    • Hematologic Oncology
    • Pediatric Oncology
  • Find a Physician
  • Find a Clinical Trial
  • Refer a Patient
  • Contact Us

Toni Choueiri, MD

Medical Oncology

Toni Choueiri, MD

View Full Profile


Related Videos

ESMO26: Toni Choueiri, MD, on KEYNOTE-564 Video

ESMO26: Toni Choueiri, MD, on KEYNOTE-564

Final analysis of the pivotal KEYNOTE-564 trial in kidney cancer presented by Toni Choueiri, MD. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma.

ESMO26: Toni Choueiri, MD on LITESPARK-012 Video

ESMO26: Toni Choueiri, MD on LITESPARK-012

Surprising results in first triplet combination study in advanced kidney cancer presented by Toni Choueiri, MD, at #ESMO26. Dr. Choueiri says even though the combination did not improve efficacy, the findings are important for informing future studies.

ASCO26: Toni Choueiri, MD, KEYNOTE-654 Video

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ...

2026 ASCO Kidney Cancer Highlights Video

2026 ASCO Kidney Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates

Kidney Cancer Highlights from ASCO 2025 Video

Kidney Cancer Highlights from ASCO 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2025.

ARC-20 Study Presented by Toni Choueiri, MD. Video

ARC-20 Study Presented by Toni Choueiri, MD.

Toni Choueiri, MD, of Dana-Farber Cancer Institute presents first results from the ARC-20 trial evaluating casdatifan (HIF-2 inhibitor) + cabozantinib (VEGF TKI) in metastatic clear cell kidney cancer.

Checkmate 214 Presented by Toni Choueiri, MD. Video

Checkmate 214 Presented by Toni Choueiri, MD.

Dr. Toni Choueiri shares groundbreaking 9-year results from the CHECKMATE-214 trial.

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan Video

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101 Video

Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101

Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib versus sunitinib in patients with advanced kidney cancer. Dana-Farber's Toni Choueiri, MD, explains more.

Connect with us

Facebook_DanaFarber_Blue_icon X_DanaFarber_Blue_icon Instagram_DanaFarber_Blue_icon Youtube_DanaFarber_Blue_icon LinkedIn_DanaFarber_Blue_icon
  • About Us
  • Research
  • Medical Oncology Spotlight
  • Transfer a Patient
  • Find a Physician
  • Refer a Patient
  • Clinical Resources
  • Dana-Farber
Powered by BroadcastMedBROADCASTMED